Stay updated on Pembrolizumab CNS Metastases Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab CNS Metastases Clinical Trial page.

Latest updates to the Pembrolizumab CNS Metastases Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedInvestigator and affiliation details were updated: Nancy Wang, M.D., Massachusetts General Hospital, with credentials added, and Priscilla Brastianos, MD, removed from the record. This reflects a change in the study's listed leadership and contact information for NCT02886585.SummaryDifference0.5%

- Check20 days agoNo Change Detected
- Check27 days agoNo Change Detected
- Check34 days agoChange DetectedThe page now displays Revision: v3.6.3, indicating a minor platform update. It affects the site’s revision label but does not modify the study information shown on the page.SummaryDifference0.0%

- Check42 days agoChange DetectedThis update adds posted results and expands the description of primary and secondary outcomes, including intracranial and extracranial endpoints and toxicity measures, with definitions and time frames. It also adds study documents (protocol and informed consent) and notes the results submission/posting dates, reflecting new data availability and end-point details.SummaryDifference3%

- Check56 days agoChange DetectedNew user guidance sections (How to Read a Study Record, Common Questions, How to Join a Study) were added and the recruitment status updated to No longer looking for participants, clarifying how to engage with the study. A formatting adjustment to the Intervention/Treatment header accompanies a version update (Revision: v3.6.0) with the older revision tag removed.SummaryDifference0.4%

- Check63 days agoChange DetectedThe page now shows a Revision: v3.5.5 tag, replacing the previous v3.5.4 tag, indicating the current software version powering the site.SummaryDifference0.1%

- Check85 days agoChange DetectedRevision: v3.5.4 replaces the previous v3.5.3 on the study page. This represents a minor site build update to the rendering template used for the record, with no change to the study data.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab CNS Metastases Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab CNS Metastases Clinical Trial page.